MEPE Antikörper (AA 201-300) (Cy5)
Kurzübersicht für MEPE Antikörper (AA 201-300) (Cy5) (ABIN1418058)
Target
Alle MEPE Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 201-300
-
Kreuzreaktivität
- Maus
-
Homologie
- Human
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human MEPE
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- MEPE (Matrix Extracellular phosphoglycoprotein (MEPE))
-
Andere Bezeichnung
- MEPE
-
Hintergrund
-
Synonyms: Matrix extracellular phosphoglycoprotein, MEPE, MEPE_HUMAN, OF45, Osteoblast/osteocyte factor 45.
Background: MEPE is a 525 amino acid extracellular matrix protein. Expressed in osteocytes and brain, MEPE is a regulator of bone metabolism that is thought to mediate mineralization and demineralization within the osteocyte microenvironment. MEPE contains an RGD cell-attachment motif and shares molecular similarities with several dentin-bone extracellular matrix RGD-containing phosphoglycoproteins, including OPN (osteopontin) and DSP (dentin sialophosphoprotein). Via its ability to control bone mineralization, MEPE is associated with various developmental events such as skeletogenesis, bone regeneration and odontogenesis. MEPE is secreted in hypophosphatemic osteomalacia tumors, suggesting a possible role in the pathophysiology of bone-related cancers.
-
Gen-ID
- 56955
Target
-